Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Core Insights - Beam Therapeutics is presenting updated safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease at the EHA2025 Congress [1][2] - BEAM-101 is a genetically modified ex vivo cell therapy aimed at treating severe sickle cell disease, specifically targeting patients with severe vaso-occlusive crises [1][5] Company Overview - Beam Therapeutics is focused on developing precision genetic medicines through base editing technology, which allows for precise modifications in the genome without causing double-stranded breaks [7] - The company aims to provide lifelong cures for serious diseases, leveraging its integrated platform for gene editing, delivery, and manufacturing [7] Clinical Trial Details - The BEACON trial is an open-label, single-arm, multicenter study evaluating the safety and efficacy of BEAM-101 in adult patients with sickle cell disease [5] - The updated dataset includes results from 17 patients, highlighting the potential of BEAM-101 as a transformative one-time treatment for sickle cell disease [2][5] Presentation Information - The presentations at EHA2025 will cover various aspects of BEAM-101, including its safety, efficacy, and the health of red blood cells post-treatment [3][4] - The conference call and webcast to review key presentations will take place on June 13, 2025, at 4:00 p.m. ET [4]